Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 25 2021 - 6:47AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
EMTN programme
update - publication of Prospectus
25 May 2021 07:00 BST
EMTN
programme update: publication of Prospectus
Following an update by AstraZeneca PLC ("AstraZeneca") of its Euro
Medium Term Note ("EMTN") programme established in 2007, the
following prospectus has been approved by the Financial
Conduct Authority and is available for viewing:
Base Prospectus for the AstraZeneca and AstraZeneca Finance LLC
U.S. $10,000,000,000 Euro Medium Term Note Programme (the
"Prospectus").
AstraZeneca Finance LLC has been added as an issuer to the EMTN
programme for 2021. Securities under the programme may therefore be
issued by either AstraZeneca or AstraZeneca Finance LLC, depending
on AstraZeneca's requirements. Any securities issued by AstraZeneca
Finance LLC will be guaranteed by AstraZeneca.
The last drawdown under the EMTN programme was in
2016.
To view the full document, please paste the following URL into the
address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/6580Z_1-2021-5-24.pdf
A copy of the above Prospectus has been submitted to the National
Storage Mechanism and will shortly be available for inspection
at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries, and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
AstraZeneca contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
25 May 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024